exemestane (Aromasin)
Jump to navigation
Jump to search
Indications
- treatment of advanced breast cancer in postmenopausal women with disease progression despite tamoxifen therapy[3]
- 5 year disease-free survival in premenopausal women higher with exemestane than with tamoxifen (91.1% vs. 87.3%)[6]
- prophylaxis for breast cancer in high-risk women[4]
- post-menopausal women with atypical ductal hyperplasia[4]
Storage
- store in orginal container
Adverse effects
Clinical significance
- 4742 women who had received 2-3 years of tamoxifen tamoxifen vs exemestane for an additional 2-3 years
- disease-free survival 87% (tamoxifen) vs 92% (exemestane)
- thromboembolic events less in exemestane group
- new cancers (non breast cancer) fewer in exemestane group
- no difference in mortality [2]
More general terms
References
- ↑ Kaiser Permanente Northern California Pharmacy update, 11/2000
- ↑ 2.0 2.1 Journal Watch 24(7):58, 2004 Coombes RC et al, N Engl J Med 350:1081, 2004 PMID: https://www.ncbi.nlm.nih.gov/pubmed/15014181 Piccart-Gebbart MJ, N Engl J Med 350:1040, 2004
- ↑ 3.0 3.1 New Evidence Supports the Third-generation Aromatase Inhibitor Exemestane (Aromasin) for Primary Breast Cancer Prescriber's Letter 11(4):22 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200408&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 4.0 4.1 4.2 Goss PE et al Exemestane for Breast-Cancer Prevention in Postmenopausal Women N Eng J Med June 4, 2011 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21639806 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1103507#t=articleTop
- ↑ 5.0 5.1 Cheung AM et al Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 2012 Feb 6. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22318095 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70389-8/abstract
Cauley JA Bone loss associated with prevention of breast cancer Lancet Oncol. 2012 Feb 6. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22318094 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970030-X/fulltext - ↑ 6.0 6.1 Pagani O et al Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med. June 1, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24881463 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1404037
- ↑ Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300622&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 8.0 8.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018